Luxeptinib (CG-806)

About Aptose Biosciences

Aptose Biosciences is a science-driven biotech focused on developing first-in-class, oral small molecule kinase inhibitors for life-threatening hematologic cancers. Its strategy centers on rationally designed, mutation-agnostic compounds that target multiple key oncogenic pathways to address resistance and broaden efficacy. The company's most advanced assets, tuspetinib for AML and luxeptinib for B-cell malignancies and AML, are in Phase 1/2 development, with promising clinical data generating interest, culminating in a definitive agreement for acquisition by Hanmi Pharmaceutical.

About Aptose Biosciences

Aptose Biosciences is a science-driven biotech focused on developing first-in-class, oral small molecule kinase inhibitors for life-threatening hematologic cancers. Its strategy centers on rationally designed, mutation-agnostic compounds that target multiple key oncogenic pathways to address resistance and broaden efficacy. The company's most advanced assets, tuspetinib for AML and luxeptinib for B-cell malignancies and AML, are in Phase 1/2 development, with promising clinical data generating interest, culminating in a definitive agreement for acquisition by Hanmi Pharmaceutical.

Therapeutic Areas